Skip to content
Search

Latest Stories

Ade Williams receives RPS Charter Award

Ade Williams receives RPS Charter Award

“Receiving the RPS Charter Award is profoundly humbling”- says Ade Williams

Adeyemi (Ade) Williams MBE, FRPharmS, a prominent figure in Bristol’s healthcare community, has been honoured with the RPS Charter Award for his exceptional contributions to pharmacy and patient care.


The Royal Pharmaceutical Society (RPS) on Tuesday announced Williams as the latest recipient of the prestigious award.

The award was presented to Williams by RPS Chief Executive Officer Paul Bennett and President Professor Claire Anderson during an event held at the DoubleTree Cadbury House Hotel in Bristol on Tuesday, June 18.

Williams, who serves as the Director and Superintendent Pharmacist of M J Williams Pharmacy Group and Leading Prescribing Pharmacist at the multi-award-winning Bedminster Pharmacy, has consistently demonstrated pharmacy’s crucial role in delivering comprehensive and affordable healthcare solutions for the community.

Williams’ dedication to pharmacy and patient care has been widely recognised. In 2022, he received an MBE for his service to the NHS and has been recognised as an NHS Vaccine Hero for his efforts in promoting vaccination access and uptake.

He is also a Fellow of the RPS, a prescribing pharmacist at Broadmead Medical Practice and a Trustee of the General Pharmaceutical Council (GPhC). Williams frequently engages with national and regional media, highlighting the important role of pharmacists in patient care.

Receiving the RPS Charter Award, Williams recalled how his first college tutor, Caroline Cook, a pharmacist, taught him the importance of "seeing people," a lesson that his pharmacist-wife, Jess, exemplified through her work.

“I am privileged that the Pharmacy profession allows us to embody such transformative values unapologetically. Liberating people from ill health and social injustice, not only enhances dignity and quality of life but also sows seeds of Hope. The trust and confidence the public places in pharmacy teams inspire us, especially me, to strive daily to make a difference within and beyond the confines of pharmacy premises.

“I am deeply grateful for the goodwill, generosity, and encouragement of so many who have enabled me in this pursuit. However, I owe an irredeemable debt to all community pharmacy colleagues, especially my team at Bedminster Pharmacy. Our collective dedication and sacrifice frames Pharmacy's narrative as stalwarts of the NHS and garners the deep affection in the many communities who have adopted us into their hearts,” he said.

RPS CEO Paul Bennett noted that Williams’ outstanding contributions to both the RPS and the wider pharmacy profession exemplify “the highest standards of commitment to improving pharmacy practice and patient care.”

RPS President, Professor Claire Anderson, added that Williams’ hard work and dedication have made a big difference in patient care and public health.

“Ade’s efforts in promoting vaccination access and supporting the community during challenging times highlight his commitment to the profession. It is a privilege to present the Charter award to Ade and I congratulate him on this and all of his achievements,” she said.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less